The evolution of targeted biologic therapies

Targeted therapies for breast cancer reflect the underlying genomic complexity of the disease. These cancers, in turn, are Darwinian constructs, acting much like species undergoing mutational events, and with environmental pressures selecting evolutionary winners and losers. It is therefore reasonable to consider the evolution of targeted biologic therapies in classic evolutionary terms. This paper will examine breast cancer therapeutics in terms of species undergoing adaptational changes as a consequence on mutational events, and will examine the prospects for new therapeutic species.